-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Etesevimab
| Category | SARS-CoV |
| CAS | 2423948-94-9 |
| Description | Etesevimab is a human recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor-binding domain. Etesevimab has been authorized for emergency use by the FDA for the treatment of COVID-19. |
Product Information
| Synonyms | CB 6; JS016 |
| Molecular Weight | 243.22 |
| Molecular Formula | C9H13N3O5 |
| Canonical SMILES | C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O |
| Appearance | Liquid |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
